

DEPARTMENT OF JUSTICE**Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—The Institute of Electrical and Electronics Engineers, Inc.**

Notice is hereby given that, on April 11, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), The Institute of Electrical and Electronics Engineers, Inc. (“IEEE”) has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing additions or changes to its standards development activities. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, 32 new standards have been initiated, and 3 existing standards are being revised. More detail regarding these changes can be found at: <https://standards.ieee.org/about/sasb/sba/21mar2024/>.

The following pre-standards activities associated with IEEE Industry Connections Activities were launched or renewed: <https://standards.ieee.org/about/bog/cag/approvals/april2024/>.

On September 17, 2004, the IEEE filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on November 3, 2004 (69 FR 64105).

The last notification was filed with the Department on February 20, 2024. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on April 16, 2024 (89 FR 26922).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024–13618 Filed 6–20–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE**Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—R Consortium, Inc.**

Notice is hereby given that, on April 22, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), R Consortium, Inc. (“R Consortium”) has filed written notifications simultaneously with the

Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, Arcus Biosciences Inc., Hayward, CA; and Sanofi, Bridgewater, NJ, have been added as parties to this venture.

No other changes have been made in either the membership or planned activity of the group research project. Membership in this group research project remains open, and R Consortium intends to file additional written notifications disclosing all changes in membership.

On September 15, 2015, R Consortium filed its original notification pursuant to section 6(a) of the Act. The Department of Justice published a notice in the **Federal Register** pursuant to section 6(b) of the Act on October 2, 2015 (80 FR 59815).

The last notification was filed with the Department on January 29, 2024. A notice was published in the **Federal Register** pursuant to section 6(b) of the Act on March 13, 2024 (89 FR 18438).

Suzanne Morris,

Deputy Director Civil Enforcement Operations, Antitrust Division.

[FR Doc. 2024–13629 Filed 6–20–24; 8:45 am]

BILLING CODE P

DEPARTMENT OF JUSTICE**Antitrust Division****Notice Pursuant to the National Cooperative Research and Production Act of 1993—Medical Technology Enterprise Consortium**

Notice is hereby given that, on April 2, 2024, pursuant to section 6(a) of the National Cooperative Research and Production Act of 1993, 15 U.S.C. 4301 *et seq.* (“the Act”), Medical Technology Enterprise Consortium (“MTEC”), has filed written notifications simultaneously with the Attorney General and the Federal Trade Commission disclosing changes in its membership. The notifications were filed for the purpose of extending the Act’s provisions limiting the recovery of antitrust plaintiffs to actual damages under specified circumstances. Specifically, 10x National Security, Aldie, VA; 4WEB, Inc., Frisco, TX; Abram Scientific, Inc., South San Francisco, CA; Admetsys Corp., Boston, MA; Advanced RNA Vaccine Technologies, Inc., North Bethesda, MD; Aergility Corp., Dunnellon, FL; Airway

Shield S.L., Santander Cantabria, Spain; AmacaThera, Inc., Toronto, CANADA; Ampel LLC, Charlottesville, VA; Anthos Group, Inc., Torrance, CA; Apos US Management, Inc., New York, NY; Asynchealth, Pebble Beach, CA; Baebies, Inc., Durham, NC; Best Practice Associates LLC dba Tria Federal, Arlington, VA; Bio-Change, Ltd., Yokneam, ISRAEL; Black Fur Biomedical, Tucson, AZ; Blue Spark Technologies, Inc., Westlake, OH; Board of Regents, Nevada System of Higher Education on behalf of the University of Nevada, Las Vegas, Las Vegas, NV; Board of the Trustees of the Colorado School of Mines, Golden, CO; Cadet NM, Inc., Albuquerque, NM; Cambridge Research & Development, Inc., Nashua, NH; Canaery, Alachua, FL; Coldplasmatech GmbH, Greifswald, GERMANY; ComeBack Mobility, Inc., New York, NY; CoolSpine LLC, Woodbury, CT; Cristae Consulting LLC, Moorestown, NJ; Directed Systems, Ltd., Cambridge, UNITED KINGDOM; Elucidern, Inc., San Diego, CA; ExThera Medical Corp., Martinez, CA; EyeYon Medical, Ltd., Ness Ziona, ISRAEL; Florida Institute of Technology, Melbourne, FL; FluidForm, Inc., Waltham, MA; Gigantor Technologies, Inc., Melbourne Beach, FL; Global Virtual Training LLC, New York, NY; GoodCap Pharmaceuticals, Toronto, CANADA; Hatch Product Development LLC, Waukegan, IL; Henley Ion LLC, New Orleans, LA; Idea Meds, Inc., New York, NY; Immense Dynamics, Inc., Bremerton, WA; Innovative Health Sciences LLC, Chester, NY; Innovosens AB, Inc., Wilmington, DE; Interoperability Institute LLC, Lansing, MI; JustBard Technologies LLC, Brunswick, MD; KaloCyte, Inc., Baltimore, MD; LaCire LLC, Alexandria, VA; Lankenau Institute for Medical Research, Wynnewood, PA; Loma Linda University, Loma Linda, CA; Lucid Reality Labs LLC, Miami, FL; LumaFlo, Inc., Detroit, MI; Lundquist Institute for Medical Innovation at Harbor-UCLA Medical Center, Torrance, CA; Medasense Biometrics, Ltd., Ramat Gan, ISRAEL; MediCarbone, Inc., Tuscon, AZ; Mitochon Pharmaceuticals, Inc., Blue Bell, PA; Modular Matter, Inc., Abingdon, MD; Moonrise Medical, Inc., Oakville, CANADA; Noleus Technologies, Inc., Houston, TX; Nou Systems, Inc., Huntsville, AL; Noxy Health Products, Inc., Anaconda, MT; Oak Grove Technologies, Raleigh, NC; Obsidian Solutions Group, Fredericksburg, VA; Omnix, Inc., San Francisco, CA; Osetomics LLC, Glen Mills, PA; Osteolyse, Inc., Soda Springs, CA; Owl Therapeutics, San Antonio,